Real-world targeted treatment for BRAF-mutant melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies how doctors use encorafenib plus binimetinib for real-world care in people with BRAF V600–mutated melanoma that can’t be removed by surgery or has spread. It may help improve understanding of which patients benefit and what happens in everyday clinical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to give consent (or the right legal process through you/your representative).
- Have advanced melanoma that cannot be removed by surgery or has metastasized, and your tumor tests positive for BRAF V600 mutation.
- Your treatment plan must be for encorafenib plus binimetinib, decided by your doctor before joining the study; you started it within the past 6 months or will start soon.
- You have either had no prior treatment for this advanced/metastatic stage, or you had exactly one prior “checkpoint inhibitor” therapy (anti-CTLA4 and/or anti-PD(L)1).
- You generally must NOT have had more than one prior checkpoint inhibitor, and no prior chemotherapy for melanoma in this setting.
- You can’t join if you’re currently in (or planning to join) another interventional trial, or if you’re on medicines for a different cancer at the same time. Also, you should not have had prior BRAF and/or MEK inhibitor treatment (with a limited exception for prior adjuvant BRAF+MEK that ended more than 6 months ago).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study looks at whether people with melanoma can get the “right” follow-up (extra) treatment based on how well their cancer responds after starting targeted drugs before surgery. The goal is to improve outcomes while better matching treatment to each person’s tumor response.
This real-world study looks at how doctors’ standard treatment works for metastatic colorectal cancer that has a specific BRAF mutation (BRAF V600E). It focuses on patients who are already starting—or will soon start—encorafenib plus cetuximab, using routine care rather than extra trial treatment.
This Phase 2 trial tests two targeted medicines (binimetinib and encorafenib) for melanoma that has spread to the brain. It focuses on people whose tumor has a specific BRAF V600 mutation and who have brain metastases that are progressing or need treatment.
This trial tests a combination of targeted drugs (encorafenib and binimetinib) followed by immunotherapy (cemiplimab and fianlimab) for people with advanced melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach can shrink tumors and help control the disease.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hear when a new Melanoma Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.